Skip to main content
Erschienen in: Rheumatology International 9/2010

01.07.2010 | Original Article

What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)

verfasst von: Xiangning Fan, Janet Pope, Murray Baron, The Canadian Scleroderma Research Group

Erschienen in: Rheumatology International | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

We studied the relationships between physician-assessed damage, severity and activity in a large, multicentre systemic sclerosis (SSc, scleroderma) cohort. We hypothesized that there is a relationship between disease activity and severity and damage, but that severity would be more strongly related to damage. A total of 520 SSc patients (87% women, mean age 56 years, mean 8.6 years disease duration, 39% diffuse SSc) were studied. The correlations between physician's global assessments of damage, activity and severity were determined overall and in a subset of early, diffuse SSc (n = 74). The mean (SD) patient global health score was 3.6 (2.4) on a 0–10 scale. Physician-rated severity, activity and damage were 2.8 (2.2), 2.3 (2.0), and 3.4 (2.4) respectively. Damage was more strongly related to severity (r = 0.744, P < 0.001) than activity (r = 0.596, P < 0.001). Damage was not related to disease duration (r = 0.046, P = 0.3). In early diffuse SSc, the correlations were: damage and severity 0.771 (P < 0.001), damage and activity 0.596 (P < 0.001), severity and activity 0.809 (P < 0.001). The relationships vary in the overall cohort versus the early diffuse SSc subset where activity, severity and damage appear more strongly related. Thus, the exact nature of the relationship between damage, activity and severity will depend upon the characteristics of the population studied.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117(3):557–567CrossRefPubMed Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117(3):557–567CrossRefPubMed
2.
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed
3.
Zurück zum Zitat Symmons DP (1995) Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol 9:267–285CrossRefPubMed Symmons DP (1995) Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol 9:267–285CrossRefPubMed
4.
Zurück zum Zitat Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 12:545–548CrossRefPubMed Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 12:545–548CrossRefPubMed
5.
Zurück zum Zitat Guillemin F (2003) Assessment of disease activity. Best Pract Res Clin Rheumatol 17:415–426CrossRefPubMed Guillemin F (2003) Assessment of disease activity. Best Pract Res Clin Rheumatol 17:415–426CrossRefPubMed
6.
Zurück zum Zitat Vonk MC, van den Hoogen FHJ, van Riel PLCM, Valentini G (2007) What does the clinician need to improve patient care in systemic sclerosis? Ann Rheum Dis 66:1129–1131CrossRefPubMed Vonk MC, van den Hoogen FHJ, van Riel PLCM, Valentini G (2007) What does the clinician need to improve patient care in systemic sclerosis? Ann Rheum Dis 66:1129–1131CrossRefPubMed
7.
Zurück zum Zitat Hudson M, Steele R, Baron M (2007) Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 37(2):93–98CrossRefPubMed Hudson M, Steele R, Baron M (2007) Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 37(2):93–98CrossRefPubMed
8.
Zurück zum Zitat Valentini G, Matucci Cerinic M (2007) Disease-specific indicators, guidelines and outcome measures in scleroderma. Clin Exp Rheumatol 25(Suppl 47):S159–S162 Valentini G, Matucci Cerinic M (2007) Disease-specific indicators, guidelines and outcome measures in scleroderma. Clin Exp Rheumatol 25(Suppl 47):S159–S162
9.
Zurück zum Zitat Ruof J, Bruhlmann P, Michel BA, Stucki G (1999) Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford) 38:535–542CrossRef Ruof J, Bruhlmann P, Michel BA, Stucki G (1999) Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford) 38:535–542CrossRef
10.
Zurück zum Zitat Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598CrossRefPubMed Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598CrossRefPubMed
11.
Zurück zum Zitat Merkel PA, Herlyn K, Martin RW et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46:2410–2420CrossRefPubMed Merkel PA, Herlyn K, Martin RW et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46:2410–2420CrossRefPubMed
12.
Zurück zum Zitat Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130–144CrossRefPubMed Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130–144CrossRefPubMed
13.
Zurück zum Zitat Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE (1990) Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33:1256–1263PubMed Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE (1990) Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33:1256–1263PubMed
14.
Zurück zum Zitat Steen V, Medsger TA Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984–1991CrossRefPubMed Steen V, Medsger TA Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984–1991CrossRefPubMed
15.
Zurück zum Zitat Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis. Development and testing. J Rheumatol 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis. Development and testing. J Rheumatol 26:2159–2167PubMed
16.
Zurück zum Zitat Geirsson AJ, Wollheim FA, Akesson A (2001) Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 60:1117–1122CrossRefPubMed Geirsson AJ, Wollheim FA, Akesson A (2001) Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 60:1117–1122CrossRefPubMed
17.
Zurück zum Zitat Gelber AC, Wigley FM (2002) Disease severity as a predictor of outcome in scleroderma. Lancet 359:277–279CrossRefPubMed Gelber AC, Wigley FM (2002) Disease severity as a predictor of outcome in scleroderma. Lancet 359:277–279CrossRefPubMed
18.
Zurück zum Zitat Arkachaisri T, Pino S (2008) Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 35:650–657CrossRefPubMed Arkachaisri T, Pino S (2008) Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 35:650–657CrossRefPubMed
20.
Zurück zum Zitat Ostojic P, Damjanov N (2006) The Scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 65:168–175CrossRefPubMed Ostojic P, Damjanov N (2006) The Scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 65:168–175CrossRefPubMed
21.
Zurück zum Zitat Clements PJ, Seibold JR, Furst DE et al (2004) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 33:249–263CrossRefPubMed Clements PJ, Seibold JR, Furst DE et al (2004) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 33:249–263CrossRefPubMed
22.
Zurück zum Zitat Poole JL, Steen VD (1991) The use of the health assessment questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31CrossRefPubMed Poole JL, Steen VD (1991) The use of the health assessment questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31CrossRefPubMed
23.
Zurück zum Zitat Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
24.
Zurück zum Zitat Valentini G, Bencivelli W, Bombardieri S et al (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 62:901–903CrossRefPubMed Valentini G, Bencivelli W, Bombardieri S et al (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 62:901–903CrossRefPubMed
25.
Zurück zum Zitat Clements PJ (2000) Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Clin Rheumatol 14:1–16CrossRef Clements PJ (2000) Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Clin Rheumatol 14:1–16CrossRef
26.
Zurück zum Zitat Derk CT, Jimenez SA (2003) Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2:181–191CrossRefPubMed Derk CT, Jimenez SA (2003) Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2:181–191CrossRefPubMed
27.
Zurück zum Zitat Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18:271–290PubMed Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18:271–290PubMed
28.
Zurück zum Zitat Johnson SR, Carette S, Dunne JV (2006) Scleroderma: health services utilization from patients’ perspective. J Rheumatol 33(6):1123–1127PubMed Johnson SR, Carette S, Dunne JV (2006) Scleroderma: health services utilization from patients’ perspective. J Rheumatol 33(6):1123–1127PubMed
29.
Zurück zum Zitat Steen VD, Medsger TA Jr, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting the development of renal involvement in progressive systemic sclerosis. Am J Med 76:779–786CrossRefPubMed Steen VD, Medsger TA Jr, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting the development of renal involvement in progressive systemic sclerosis. Am J Med 76:779–786CrossRefPubMed
30.
Zurück zum Zitat Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289CrossRefPubMed Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289CrossRefPubMed
31.
Zurück zum Zitat Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2–10CrossRefPubMed Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2–10CrossRefPubMed
32.
Zurück zum Zitat Steen VD, Medsger TA Jr (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefPubMed Steen VD, Medsger TA Jr (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefPubMed
33.
Zurück zum Zitat Henness S, Wigley FM (2007) Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol 19:611–618CrossRefPubMed Henness S, Wigley FM (2007) Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol 19:611–618CrossRefPubMed
34.
Zurück zum Zitat Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR (2007) Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther 9(Suppl):S7CrossRefPubMed Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR (2007) Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther 9(Suppl):S7CrossRefPubMed
Metadaten
Titel
What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)
verfasst von
Xiangning Fan
Janet Pope
Murray Baron
The Canadian Scleroderma Research Group
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 9/2010
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1129-7

Weitere Artikel der Ausgabe 9/2010

Rheumatology International 9/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.